{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54","upperLimit":"78","value":"66"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"}],"units":"Participants"}],"description":"Overall survival was defined as time from registration to death from any cause. Patients alive at last follow-up were censored. The 2-year overall survival rate was defined as the percentage of patients that were still alive two years after registration into the study. Kaplan-Meier estimate of 2-year overall survival was calculated in the 60 eligible and treated patients.","dispersionType":"95% Confidence Interval","groups":[{"description":"* Cetuximab therapy: Patients receive an initial loading dose of cetuximab intravenously (IV) over 2 hours on day 1. Patients then receive cetuximab IV over 1 hour on days 8, 15, 22, 29, 36, 43, 50, and 57.\n* Chemoradiotherapy: Beginning on day 15 of cetuximab therapy, patients undergo radiotherapy once daily, 5 days a week, for at least 7 weeks. Patients also receive cisplatin IV over 1-2 hours on days 15, 36, and 57.\n* Cetuximab maintenance therapy: After the completion of chemoradiotherapy, patients continue to receive cetuximab IV over 1 hour once weekly for 6-12 months.","id":"OG000","title":"Cisplatin, C225, Radiation"}],"paramType":"NUMBER","populationDescription":"Eligible and treated","reportingStatus":"POSTED","timeFrame":"assessed very 3 months for 2 years","title":"2-year Overall Survival Rate","type":"SECONDARY","unitOfMeasure":"proportion of participants"}